I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ASH 2020

Coming soon
09:30 AM
Duration 10mins Virtual
Effect of Moderate and Severe Hemophilia A on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis
Khair K, Nissen F, Silkey M, Burke T, Shang A, Aizenas M, Meier O, O’Hara J, Noone D
10:00 AM
Duration 10mins Virtual
Five-Year Analysis of MURANO Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy
Kater AP, Kipps TJ, Eichhorst BF, Hillmen P, D'Rozario J, Owen C, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Wilson C, Wu J, Jiang Y, Lefebure M, Boyer M, Seymour JF
10:30 AM
Duration 10mins Virtual
Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, phase 3 CLL14 trial
Al-Sawaf O, Zhang C, Robrecht S, Wilson C, Tandon M, Ching T, Fink A-M, Tausch E, Ritgen M, Kreuzer K-A, Schary W, Wendtner C-M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K
02:30 PM
Duration 10mins Virtual
Initial Clinical Activity and Safety of Cevostamab (BFCR4350A), a FcRH5xCD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Cohen AD, Harrison S, Krishnan A, Fonseca R, Forsberg PA, Spencer A, Berdeja JG, Laubach JP, Li M, Choeurng V, Vaze A, Samenini D, Sumiyoshi T, Cooper J, Fine BM, Trudel S
03:15 PM
Duration 10mins Virtual
Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib (Cobi) as a Single Agent and in Combination with Venetoclax (Ven) with or without Atezolizumab (Atezo) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Schjesvold F, Ribrag V, Rodriguez-Otero P, Robak PJ, Hansson M, Hajek R, Alegre Amor A, Martinez-Lopez J, Onishi M, Gallo JD, Raval A, Deshpande S, Malhi V, Hong W-J, Raab MS
12:15 PM
Duration 10mins Virtual
Single-agent Mosunetuzumab is a Promising, Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑cell Lymphoma
Olszewski A, Avigdor A, Babu S, Levi I, Abadi U, Holmes H, McKinney M, Horowitz N, McCord R, Xie Y, Chen C, Sarouei K, Qayum N, O'Hear C, Sellam G, Eradat H
12:45 PM
Duration 10mins Virtual
Glofitamab Step-Up Dosing Induces High Response Rates in Patients with Hard-to-treat Refractory or Relapsed (R/R) Non-Hodgkin Lymphoma (NHL)
Hutchings M, Carlo-Stella C, Bachy E, Offner FC, Morschhauser F, Crump M, Iacoboni G, Sureda A, Martinez-Lopez J, Lundberg L, Dixon M, Perez Callejo D, Relf J, Carlile D, Piccione E, Humphrey K, Dickinson MJ
02:00 PM
Duration 10mins Virtual
Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
Mascarenhas J, Anders A, Burbury K, El-Galaly T, Gerds A, Gupta V, Higgins B, Kovic B, Maffioli M, Mesa R, Palmer J, Passamonti F, Rambaldi A, Ross D, Vannucchi A, Yacoub A
07:30 AM
09:30 AM
Duration 10mins Virtual
Polatuzumab Vedotin plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Gritti G, Marlton P, Phillips T, Arthur C, Bannerji R, Corradini P, Johnston A, Seymour JF, Yuen S, Hirata J, Musick L, Saha S, Croft B, Flowers C
02:00 PM
Duration 10mins Virtual
Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
Assouline S, Kim WS, Sehn LH, Schuster SJ, Cheah CY, Nastoupl LJ, Shadman M, Yoon SS, Matasar MJ, Diefenbach C, Gregory GP, Bartlett NL, Wei MC, Doral MY, Yin S, Negricea R, Li C-C, Penuel E, Huang H, Budde LE